This is a blog by UW Tacoma faculty and students interested in economics. It publishes commentaries on the economics of education, health, immigration, labor, trade, and urban policies.
– William Monkman, student
The Child Tax Credit (CTC) has recently increased: the 2017 Tax Cut and Jobs Act doubled the CTC from $1,000 to $2,000 per child and entitled parents whose federal liabilities are less than their CTC to receive an additional $1,400. The CTC, in terms of its share in income, is relatively worth more to low-income earners than high-income earners. Because of the additional $1,400, it can even be argued as a progressive subsidy. Continue reading
– Aaron Hansen, student
The Affordable Care Act (ACA) has been the topic of debates and political rhetoric quite a bit in the past 18 months. Our national government has been working to replace the ACA and scale back the federal regulations that came along with it. It is a hot button topic and a confusing one. Let us examine two questions so that we might better understand the motivations of future proposals. Who is healthcare reform for? Who drives the policy changes? Continue reading
– Hibaq Abdullahi, student
In the United States, individuals with criminal histories will regularly experience re-arrest, reconviction, resentencing, or return to prison after their first conviction. This phenomenon, known as recidivism, represents an enormous financial burden to society in the form of lost wages and the costs of incarceration; one 1994 study of 15 states found recidivism rates over 66% in as little as three years after release from prison. Attempts to reduce recidivism often focus on employment opportunities: the difficulty that former convicts face in getting a job may explain their propensity to repeat criminal activity. Continue reading
– Vinny Wilson, student
Not long ago, Americans were not able to consume a drug without risking adverse effects or even death. Today, the American healthcare system provides safe and innovative drugs under the supervision of the Food and Drug Administration (FDA). Continue reading
– David Kind, student
A vigilant agency may take extra time in its approval process to ensure the safety and efficacy of a drug. However, the extra time comes at the cost lives that could have been saved provided that the drugs were approved faster. How can the FDA find a balance between the two?